ASCEND was a multicenter, placebo-controlled trial that aimed to investigate the effects of the endothelin-A (ET A ... end-stage renal disease, or death. Secondary outcomes included changes ...

AZ’s ZENITH-CKD study looked at the combination of its SGLT2 drug dapagliflozin with zibotentan, an endothelin A (ETA ... with an increased risk of kidney function loss over time, so a key ...